McMullan P, Grant-Kels JM. Childhood and adolescent melanoma: An update.
Clin Dermatol 2025:S0738-081X(25)00027-6. [PMID:
39909213 DOI:
10.1016/j.clindermatol.2025.01.010]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2025]
Abstract
Pediatric melanoma is a rare but clinically significant public health concern, as it accounts for 7% of all malignancies in adolescents aged 15 to 19. Given the overall rarity of pediatric melanoma, especially in preadolescents, patients can go undetected, leading to a delay in treatment. We divide pediatric melanoma subtypes into three distinct age ranges-infantile, preadolescent, and adolescent-and distinguish the clinical features, prognosis, and associated risk factors of each age range. We next summarize the three predominant melanoma subtypes-Spitzoid melanoma, congenital melanocytic nevus-associated melanoma, and conventional (adult-type) melanoma-and provide distinguishing clinical, histologic, and genetic features from their difficult-to-differentiate benign counterparts. We conclude by reviewing consensus guidelines for pediatric melanoma staging and treatment, with a special emphasis on outlining barriers to adapting the advancements in targeted therapeutics into the standard care of pediatric melanoma.
Collapse